Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Prelude to the real arguments

The final Markman hearing in Amgen Inc.'s erythropoietin patent infringement suit against Transkaryotic Therapies Inc. and Aventis Pharmaceuticals shed perhaps even less light on the issues that will decide the case than did the previous two hearings into AMGN's patent claims. In any case, the judge in the case last week made clear that the outcome ultimately will turn on upcoming arguments about whether AMGN in fact enabled the claims in its patents for EPO.

Last week's hearing did serve to define six additional disputed terms in AMGN's patent claims, and gave some insight into the arguments each side may use once the trial begins following a final pre-trial hearing scheduled for this week.

Young adopted definitions of claim terms found in AMGN's patents, covering the DNA constructs used to

Read the full 1296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE